Spero therapeutics provides update on spr720 phase 2a clinical trial

Cambridge, mass., feb. 05, 2021 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the united states food and drug administration (fda) informed spero that a clinical hold has been placed on its phase 2a clinical trial of spr720, spero's investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (ntm-pd).
SPRO Ratings Summary
SPRO Quant Ranking